Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL776698 | 0.82 | CA1 (0.33) | CA1CA2CA7CA13 | |
| SCHEMBL14669110 | 0.82 | CA1 (0.33) | CA1CA2CA7CA13 | |
| Iodide SCHEMBL7252284 | 0.80 | CA1 (0.32) | CA1CA2CA7CA13 | |
| SCHEMBL5984726 | 0.78 | CA1 (0.30) | CA1CA2CA7CA13 | |
| SCHEMBL19520098 | 0.76 | — | — | |
| SCHEMBL286824 | 0.75 | CA1 (0.37) | CA1CA2CA7CA13 | |
| SCHEMBL10685320 | 0.74 | ALDH1A1 (0.37) | — | |
| SCHEMBL8649495 | 0.74 | ALDH1A1 (0.37) | — | |
| SCHEMBL25871898 | 0.74 | — | — | |
| SCHEMBL4124586 | 0.74 | CA2 (0.32) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115411363-A | Electrolyte, secondary battery and electric equipment | 欣旺达电动汽车电池有限公司 | 2022-11-29 | — | — | CN | claimed |
| EP-2097401-A1 | PROCESSES FOR THE PREPARATION OF (3R, 4R) -N- (4 -CHLOROPHENYL) -1- (2, 2-DIFLUOROETHYL) -N' - [2-FLUORO-4- (2-OXO-1 (2H) -PYRIDINYL) PHENYL]-3, 4-PYRROLIDINEDICARBOXAMIDE | F. Hoffmann-Roche AG (CH) | 2009-09-09 | — | — | EP | claimed |
| US-20080214826-A1 | PROCESSES FOR THE MANUFACTURE OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | HOFFMANN-LA ROCHE, INC. | 2008-09-04 | — | — | US | claimed |
| WO-2008077797-A1 | PROCESSES FOR THE PREPARATION OF (3R, 4R) -N- (4 -CHLOROPHENYL) -1- (2, 2-DIFLUOROETHYL) -N' - [2-FLUORO-4- (2-OXO-1 (2H) -PYRIDINYL) PHENYL] -3, 4-PYRROLIDINEDICARBOXAMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | claimed |
| EP-4431509-B1 | NOVEL NON-FLUORINATED QUINOLONE COMPOUND AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO LTD BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2026-01-21 | — | — | EP | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-20250042912-A1 | NOVEL NON-FLUORINATED QUINOLONE COMPOUND AND USE THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4489738-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| CN-118510758-A | RXFP1 agonists | 百时美施贵宝公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118355004-A | Cyclopropyl- (heteroaryl) -substituted ethylsulfonyl-pyridine derivatives | 勃林格殷格翰动物保健有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118339162-A | Novel non-fluoroquinolone compounds and application thereof | 广州白云山医药集团股份有限公司白云山制药总厂 | 2024-07-12 | — | — | CN | disclosed |
| CN-118317774-A | Pharmaceutical compositions comprising quinazoline compounds | 安斯泰来制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| WO-2008119663-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080214826-A1 | PROCESSES FOR THE MANUFACTURE OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | HOFFMANN-LA ROCHE, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008077797-A1 | PROCESSES FOR THE PREPARATION OF (3R, 4R) -N- (4 -CHLOROPHENYL) -1- (2, 2-DIFLUOROETHYL) -N' - [2-FLUORO-4- (2-OXO-1 (2H) -PYRIDINYL) PHENYL] -3, 4-PYRROLIDINEDICARBOXAMIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008071918-A1 | PYRIDO-PYRAZINE DERIVATIVES USEFUL AS HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
| EP-1047656-A4 | ALKENYLDIARYLMETHANE NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6569897-B1 | Such as 3',3\"-dibromo-4',4\"-dimethyoxy-5',5\"-bis(methyoxy carbonyl)-1,1-diphenylethene | PURDUE RESEARCH FOUNDATION | 2003-05-27 | — | — | US | disclosed |
| EP-1047656-A1 | ALKENYLDIARYLMETHANE NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036384-A1 | ALKENYLDIARYLMETHANE NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042912-A1 | NOVEL NON-FLUORINATED QUINOLONE COMPOUND AND USE THEREOF | NQO2, Q6ZSR9, NRAS | CA1 4133/4885CA2 3825/4885CA7 1717/4885 |
| US-20080214826-A1 | PROCESSES FOR THE MANUFACTURE OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | ALDH18A1, CPS1, DHPS | CA1 1825/4885CA2 1265/4885CA7 823/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | CA1 615/4885CA2 522/4885CA7 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.